| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft Rejection | 115 | 2026 | 1186 | 14.050 |
Why?
|
| Transplantation Tolerance | 39 | 2026 | 145 | 11.300 |
Why?
|
| B-Lymphocytes | 42 | 2026 | 727 | 8.180 |
Why?
|
| Isoantibodies | 33 | 2025 | 135 | 7.570 |
Why?
|
| Organ Transplantation | 26 | 2024 | 306 | 6.820 |
Why?
|
| Heart Transplantation | 63 | 2026 | 873 | 6.210 |
Why?
|
| Graft Survival | 54 | 2026 | 994 | 5.030 |
Why?
|
| Immune Tolerance | 28 | 2025 | 386 | 4.740 |
Why?
|
| Kidney Transplantation | 28 | 2025 | 939 | 4.310 |
Why?
|
| T-Lymphocytes | 41 | 2026 | 1327 | 3.990 |
Why?
|
| Transplantation, Heterologous | 40 | 2025 | 375 | 3.210 |
Why?
|
| Immunosuppressive Agents | 53 | 2017 | 1013 | 3.190 |
Why?
|
| Immunologic Memory | 14 | 2024 | 188 | 3.070 |
Why?
|
| Isoxazoles | 41 | 2006 | 81 | 2.890 |
Why?
|
| CD40 Ligand | 14 | 2026 | 79 | 2.880 |
Why?
|
| CD4-Positive T-Lymphocytes | 16 | 2025 | 502 | 2.630 |
Why?
|
| Mice | 131 | 2026 | 12697 | 2.610 |
Why?
|
| Mice, Inbred BALB C | 44 | 2026 | 1110 | 2.570 |
Why?
|
| Skin Transplantation | 14 | 2024 | 191 | 2.460 |
Why?
|
| Allografts | 19 | 2026 | 218 | 2.430 |
Why?
|
| Animals | 187 | 2026 | 28893 | 2.420 |
Why?
|
| Transplantation, Homologous | 43 | 2025 | 1026 | 2.400 |
Why?
|
| Mice, Inbred C57BL | 55 | 2026 | 3598 | 2.300 |
Why?
|
| Isoantigens | 13 | 2026 | 74 | 2.010 |
Why?
|
| Lymphocyte Activation | 24 | 2017 | 822 | 1.980 |
Why?
|
| CD8-Positive T-Lymphocytes | 12 | 2026 | 696 | 1.960 |
Why?
|
| HLA Antigens | 9 | 2023 | 238 | 1.690 |
Why?
|
| Germinal Center | 5 | 2025 | 66 | 1.680 |
Why?
|
| Immunity, Humoral | 4 | 2018 | 76 | 1.570 |
Why?
|
| Islets of Langerhans Transplantation | 16 | 2012 | 286 | 1.520 |
Why?
|
| Fetus | 3 | 2025 | 237 | 1.450 |
Why?
|
| T-Lymphocytes, Regulatory | 10 | 2025 | 358 | 1.430 |
Why?
|
| Th1 Cells | 3 | 2025 | 173 | 1.390 |
Why?
|
| Transplantation Immunology | 8 | 2019 | 83 | 1.390 |
Why?
|
| Tissue Donors | 14 | 2026 | 581 | 1.370 |
Why?
|
| CTLA-4 Antigen | 8 | 2016 | 146 | 1.360 |
Why?
|
| Immunoglobulin G | 12 | 2023 | 480 | 1.360 |
Why?
|
| Nanofibers | 8 | 2026 | 33 | 1.360 |
Why?
|
| Diabetes Mellitus, Experimental | 12 | 2013 | 207 | 1.320 |
Why?
|
| Disaccharides | 11 | 2008 | 24 | 1.230 |
Why?
|
| Antibodies, Monoclonal | 20 | 2023 | 1416 | 1.220 |
Why?
|
| Interferon-gamma | 16 | 2025 | 479 | 1.220 |
Why?
|
| Listeriosis | 6 | 2019 | 91 | 1.210 |
Why?
|
| Toll-Like Receptors | 6 | 2009 | 106 | 1.180 |
Why?
|
| Listeria monocytogenes | 5 | 2019 | 98 | 1.170 |
Why?
|
| Galactosyltransferases | 11 | 2014 | 37 | 1.140 |
Why?
|
| Abatacept | 9 | 2020 | 89 | 1.120 |
Why?
|
| Major Histocompatibility Complex | 5 | 2023 | 88 | 1.110 |
Why?
|
| Antigen-Presenting Cells | 7 | 2024 | 146 | 1.100 |
Why?
|
| T-Lymphocyte Subsets | 9 | 2019 | 291 | 1.080 |
Why?
|
| Humans | 122 | 2026 | 98053 | 1.060 |
Why?
|
| Killer Cells, Natural | 13 | 2008 | 297 | 1.060 |
Why?
|
| Rats, Inbred Lew | 38 | 2008 | 219 | 1.050 |
Why?
|
| Histocompatibility Antigens Class II | 7 | 2025 | 174 | 1.010 |
Why?
|
| B-Lymphocytes, Regulatory | 3 | 2019 | 9 | 1.000 |
Why?
|
| Mice, Transgenic | 18 | 2026 | 1604 | 0.980 |
Why?
|
| Bacterial Infections | 4 | 2014 | 184 | 0.980 |
Why?
|
| Disease Models, Animal | 14 | 2024 | 2572 | 0.960 |
Why?
|
| Antibodies | 11 | 2022 | 348 | 0.950 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2023 | 150 | 0.940 |
Why?
|
| Rats | 54 | 2023 | 4071 | 0.940 |
Why?
|
| Dendritic Cells | 5 | 2025 | 552 | 0.920 |
Why?
|
| Insulin-Secreting Cells | 4 | 2013 | 453 | 0.900 |
Why?
|
| Parity | 1 | 2025 | 96 | 0.890 |
Why?
|
| Spleen | 12 | 2020 | 375 | 0.870 |
Why?
|
| B-Lymphocyte Subsets | 3 | 2018 | 37 | 0.830 |
Why?
|
| Primary Graft Dysfunction | 1 | 2024 | 49 | 0.820 |
Why?
|
| Immunoconjugates | 6 | 2016 | 138 | 0.810 |
Why?
|
| Phenanthrenes | 1 | 2023 | 4 | 0.810 |
Why?
|
| Diterpenes | 1 | 2023 | 24 | 0.800 |
Why?
|
| Staphylococcus aureus | 9 | 2022 | 290 | 0.800 |
Why?
|
| Prodrugs | 1 | 2023 | 53 | 0.780 |
Why?
|
| Mice, Knockout | 29 | 2019 | 2207 | 0.780 |
Why?
|
| Signal Transduction | 14 | 2026 | 3620 | 0.770 |
Why?
|
| Th2 Cells | 3 | 2025 | 152 | 0.770 |
Why?
|
| Staphylococcal Infections | 5 | 2022 | 286 | 0.770 |
Why?
|
| Sugars | 1 | 2022 | 5 | 0.750 |
Why?
|
| Female | 55 | 2026 | 51525 | 0.750 |
Why?
|
| Regeneration | 5 | 2014 | 162 | 0.740 |
Why?
|
| Antigens | 5 | 2022 | 225 | 0.710 |
Why?
|
| Antibody Formation | 14 | 2022 | 172 | 0.710 |
Why?
|
| Kidney | 11 | 2025 | 1123 | 0.700 |
Why?
|
| Influenza Vaccines | 3 | 2026 | 176 | 0.700 |
Why?
|
| Adaptive Immunity | 6 | 2020 | 193 | 0.700 |
Why?
|
| Cyclosporine | 20 | 2000 | 241 | 0.690 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 327 | 0.690 |
Why?
|
| Cytokines | 10 | 2025 | 889 | 0.680 |
Why?
|
| Inflammation | 9 | 2025 | 1120 | 0.670 |
Why?
|
| Pregnancy | 6 | 2025 | 3244 | 0.670 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2021 | 11 | 0.670 |
Why?
|
| Diabetes Mellitus, Type 1 | 7 | 2012 | 686 | 0.660 |
Why?
|
| Interleukin-10 | 3 | 2017 | 167 | 0.660 |
Why?
|
| Lung Transplantation | 2 | 2024 | 390 | 0.660 |
Why?
|
| Killer Cells, Lymphokine-Activated | 10 | 1996 | 27 | 0.630 |
Why?
|
| Pancreas Transplantation | 6 | 2008 | 120 | 0.620 |
Why?
|
| Autoimmunity | 3 | 2019 | 195 | 0.610 |
Why?
|
| Congresses as Topic | 1 | 2020 | 123 | 0.600 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2016 | 321 | 0.590 |
Why?
|
| Peptides | 9 | 2023 | 669 | 0.590 |
Why?
|
| Transplants | 3 | 2022 | 43 | 0.590 |
Why?
|
| Desensitization, Immunologic | 1 | 2019 | 48 | 0.580 |
Why?
|
| Plasma Cells | 3 | 2017 | 89 | 0.570 |
Why?
|
| Complement Activation | 3 | 2008 | 88 | 0.570 |
Why?
|
| Mice, Inbred C3H | 12 | 2011 | 370 | 0.570 |
Why?
|
| Histocompatibility Antigens Class I | 5 | 2023 | 212 | 0.560 |
Why?
|
| Adjuvants, Immunologic | 6 | 2020 | 176 | 0.560 |
Why?
|
| Apoptosis | 5 | 2023 | 1752 | 0.550 |
Why?
|
| Male | 55 | 2026 | 47062 | 0.540 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 2023 | 106 | 0.540 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2026 | 446 | 0.530 |
Why?
|
| Immunologic Techniques | 1 | 2017 | 25 | 0.530 |
Why?
|
| Receptors, IgG | 7 | 2008 | 70 | 0.530 |
Why?
|
| Lung | 5 | 2024 | 1407 | 0.520 |
Why?
|
| Tumor Necrosis Factor-alpha | 15 | 2017 | 707 | 0.520 |
Why?
|
| Staphylococcal Skin Infections | 4 | 2022 | 25 | 0.520 |
Why?
|
| Interleukin-2 | 13 | 2022 | 246 | 0.510 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 769 | 0.510 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 2373 | 0.500 |
Why?
|
| Cytotoxicity, Immunologic | 9 | 1995 | 218 | 0.490 |
Why?
|
| Antigens, Differentiation | 7 | 2004 | 125 | 0.480 |
Why?
|
| Transplantation, Heterotopic | 11 | 2010 | 46 | 0.470 |
Why?
|
| B7-H1 Antigen | 4 | 2023 | 332 | 0.460 |
Why?
|
| Clonal Deletion | 3 | 2020 | 24 | 0.460 |
Why?
|
| Antigens, CD | 13 | 2018 | 484 | 0.450 |
Why?
|
| Monitoring, Immunologic | 2 | 2015 | 20 | 0.450 |
Why?
|
| Models, Animal | 6 | 2024 | 279 | 0.450 |
Why?
|
| Interleukin-6 | 3 | 2011 | 282 | 0.440 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 977 | 0.440 |
Why?
|
| Cell Proliferation | 6 | 2019 | 1790 | 0.440 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2018 | 99 | 0.430 |
Why?
|
| Luciferases | 4 | 2013 | 128 | 0.430 |
Why?
|
| Allergy and Immunology | 1 | 2015 | 18 | 0.430 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 372 | 0.430 |
Why?
|
| Laboratories | 1 | 2015 | 47 | 0.430 |
Why?
|
| Cell Lineage | 1 | 2016 | 332 | 0.430 |
Why?
|
| Kidney Failure, Chronic | 2 | 2021 | 445 | 0.420 |
Why?
|
| International Cooperation | 1 | 2015 | 132 | 0.420 |
Why?
|
| Precision Medicine | 1 | 2019 | 503 | 0.420 |
Why?
|
| Biomedical Research | 2 | 2020 | 471 | 0.420 |
Why?
|
| Antiviral Agents | 5 | 2006 | 369 | 0.420 |
Why?
|
| Islets of Langerhans | 7 | 2010 | 568 | 0.410 |
Why?
|
| CD3 Complex | 8 | 2012 | 137 | 0.410 |
Why?
|
| Lymph Nodes | 5 | 2024 | 560 | 0.410 |
Why?
|
| Immunization | 4 | 2024 | 154 | 0.410 |
Why?
|
| Antibodies, Bacterial | 4 | 2022 | 106 | 0.400 |
Why?
|
| Membrane Glycoproteins | 9 | 1998 | 446 | 0.390 |
Why?
|
| Uracil | 1 | 2013 | 58 | 0.390 |
Why?
|
| Transplantation | 3 | 2024 | 39 | 0.380 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 1998 | 304 | 0.380 |
Why?
|
| Communicable Diseases | 1 | 2014 | 74 | 0.380 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 76 | 0.380 |
Why?
|
| Antibodies, Heterophile | 5 | 2004 | 20 | 0.380 |
Why?
|
| Societies, Medical | 4 | 2022 | 682 | 0.380 |
Why?
|
| Immunodominant Epitopes | 2 | 2025 | 25 | 0.380 |
Why?
|
| Up-Regulation | 4 | 2010 | 743 | 0.370 |
Why?
|
| Gender Identity | 2 | 2023 | 59 | 0.360 |
Why?
|
| Immunity, Innate | 4 | 2024 | 481 | 0.360 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2026 | 59 | 0.360 |
Why?
|
| Piperidines | 1 | 2013 | 172 | 0.350 |
Why?
|
| Bone Transplantation | 2 | 2003 | 82 | 0.350 |
Why?
|
| Epitopes | 9 | 2017 | 258 | 0.350 |
Why?
|
| Receptors, Immunologic | 6 | 1996 | 142 | 0.350 |
Why?
|
| Blood Glucose | 6 | 2016 | 911 | 0.350 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 101 | 0.350 |
Why?
|
| Cytomegalovirus | 3 | 2006 | 74 | 0.340 |
Why?
|
| CD4 Antigens | 6 | 2007 | 81 | 0.340 |
Why?
|
| Cytomegalovirus Infections | 4 | 2006 | 116 | 0.340 |
Why?
|
| Hydroxybutyrates | 4 | 1999 | 25 | 0.330 |
Why?
|
| Vaccines, Subunit | 4 | 2020 | 54 | 0.330 |
Why?
|
| Aniline Compounds | 4 | 1999 | 64 | 0.320 |
Why?
|
| Tacrolimus | 6 | 2013 | 376 | 0.320 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 412 | 0.310 |
Why?
|
| Lymphocyte Depletion | 3 | 2010 | 103 | 0.300 |
Why?
|
| Liver | 8 | 2008 | 1231 | 0.300 |
Why?
|
| Administration, Intranasal | 3 | 2026 | 141 | 0.300 |
Why?
|
| Treatment Outcome | 8 | 2020 | 9708 | 0.300 |
Why?
|
| Bacteria | 1 | 2014 | 545 | 0.290 |
Why?
|
| Down-Regulation | 1 | 2010 | 529 | 0.290 |
Why?
|
| Immunoglobulin M | 8 | 2014 | 153 | 0.290 |
Why?
|
| Phenotype | 9 | 2016 | 2638 | 0.290 |
Why?
|
| Insulin | 2 | 2013 | 1225 | 0.280 |
Why?
|
| Uridine | 9 | 2006 | 57 | 0.280 |
Why?
|
| Swine | 11 | 2025 | 592 | 0.280 |
Why?
|
| Graft vs Host Disease | 3 | 2009 | 379 | 0.270 |
Why?
|
| Lymphoproliferative Disorders | 3 | 1997 | 105 | 0.270 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 6 | 1994 | 98 | 0.270 |
Why?
|
| Reperfusion Injury | 6 | 2024 | 148 | 0.270 |
Why?
|
| Time Factors | 15 | 2016 | 5567 | 0.270 |
Why?
|
| Cricetinae | 13 | 2000 | 533 | 0.270 |
Why?
|
| alpha-Galactosidase | 1 | 2007 | 5 | 0.270 |
Why?
|
| Histocompatibility | 4 | 2023 | 71 | 0.270 |
Why?
|
| CD59 Antigens | 1 | 2007 | 17 | 0.270 |
Why?
|
| Biomarkers | 4 | 2023 | 2020 | 0.270 |
Why?
|
| Proteomics | 3 | 2025 | 279 | 0.260 |
Why?
|
| Ischemic Preconditioning | 2 | 2006 | 37 | 0.260 |
Why?
|
| Biphenyl Compounds | 2 | 1998 | 63 | 0.260 |
Why?
|
| Antigens, Surface | 1 | 2007 | 100 | 0.260 |
Why?
|
| Heterografts | 2 | 2025 | 121 | 0.260 |
Why?
|
| Mesocricetus | 12 | 2000 | 103 | 0.250 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 291 | 0.250 |
Why?
|
| Autoimmune Diseases | 3 | 1998 | 259 | 0.250 |
Why?
|
| Leukocyte Common Antigens | 3 | 1995 | 50 | 0.250 |
Why?
|
| Risk Factors | 5 | 2024 | 6231 | 0.250 |
Why?
|
| NF-kappa B | 4 | 2023 | 423 | 0.250 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 194 | 0.240 |
Why?
|
| Bone Marrow Transplantation | 3 | 2023 | 286 | 0.240 |
Why?
|
| Apolipoprotein L1 | 1 | 2026 | 8 | 0.240 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2026 | 3 | 0.240 |
Why?
|
| Freund's Adjuvant | 1 | 2006 | 25 | 0.240 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 467 | 0.240 |
Why?
|
| Consensus | 2 | 2020 | 315 | 0.240 |
Why?
|
| Cell Transplantation | 1 | 2006 | 46 | 0.240 |
Why?
|
| Endothelium, Vascular | 3 | 2003 | 440 | 0.220 |
Why?
|
| Calcium Signaling | 1 | 2026 | 142 | 0.220 |
Why?
|
| Mice, Inbred Strains | 6 | 2015 | 281 | 0.220 |
Why?
|
| Cells, Cultured | 12 | 2007 | 2855 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2555 | 0.220 |
Why?
|
| Interferon Regulatory Factors | 2 | 2017 | 76 | 0.220 |
Why?
|
| Exotoxins | 2 | 2022 | 21 | 0.220 |
Why?
|
| Cell Adhesion Molecules | 3 | 1994 | 184 | 0.220 |
Why?
|
| Cell Differentiation | 7 | 2018 | 1646 | 0.220 |
Why?
|
| Histocompatibility Testing | 3 | 2023 | 145 | 0.220 |
Why?
|
| Acute Disease | 6 | 2009 | 860 | 0.220 |
Why?
|
| Genes, Reporter | 4 | 2019 | 276 | 0.210 |
Why?
|
| Lupus Nephritis | 1 | 2025 | 85 | 0.210 |
Why?
|
| Skin | 2 | 2019 | 591 | 0.210 |
Why?
|
| Flow Cytometry | 6 | 2018 | 720 | 0.210 |
Why?
|
| Sex Factors | 3 | 2024 | 1138 | 0.200 |
Why?
|
| Epoxy Compounds | 1 | 2023 | 10 | 0.200 |
Why?
|
| Alleles | 2 | 2026 | 1159 | 0.200 |
Why?
|
| Antilymphocyte Serum | 2 | 2020 | 68 | 0.200 |
Why?
|
| Cross-Priming | 1 | 2023 | 59 | 0.200 |
Why?
|
| Cell Line | 12 | 2017 | 2482 | 0.190 |
Why?
|
| Transplantation Chimera | 3 | 2023 | 84 | 0.190 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2023 | 27 | 0.190 |
Why?
|
| Macrophages | 5 | 2025 | 643 | 0.190 |
Why?
|
| Organ Specificity | 2 | 2022 | 287 | 0.190 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2022 | 6 | 0.190 |
Why?
|
| Immunoglobulin Class Switching | 2 | 2016 | 38 | 0.190 |
Why?
|
| Antibody Specificity | 2 | 2020 | 126 | 0.190 |
Why?
|
| Myeloid Differentiation Factor 88 | 4 | 2012 | 59 | 0.180 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2020 | 112 | 0.180 |
Why?
|
| Leukocidins | 1 | 2022 | 3 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2024 | 213 | 0.180 |
Why?
|
| Sex | 1 | 2021 | 6 | 0.180 |
Why?
|
| Chronic Disease | 2 | 2024 | 984 | 0.180 |
Why?
|
| Streptozocin | 2 | 2013 | 57 | 0.180 |
Why?
|
| Microbiota | 3 | 2019 | 467 | 0.180 |
Why?
|
| CD8 Antigens | 3 | 2000 | 82 | 0.170 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 4 | 1995 | 11 | 0.170 |
Why?
|
| Europe | 2 | 2020 | 356 | 0.170 |
Why?
|
| Publications | 1 | 2021 | 32 | 0.170 |
Why?
|
| Liver Transplantation | 9 | 2002 | 1235 | 0.170 |
Why?
|
| DNA-Binding Proteins | 5 | 2013 | 1255 | 0.170 |
Why?
|
| Honey | 1 | 2000 | 3 | 0.170 |
Why?
|
| Botulism | 1 | 2000 | 6 | 0.170 |
Why?
|
| Interleukin-17 | 2 | 2014 | 113 | 0.170 |
Why?
|
| Anterior Eye Segment | 1 | 2020 | 10 | 0.160 |
Why?
|
| Tyrosine | 5 | 1999 | 135 | 0.160 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 86 | 0.160 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2020 | 6 | 0.160 |
Why?
|
| Gene Expression Regulation | 7 | 2021 | 2023 | 0.160 |
Why?
|
| Trans-Activators | 3 | 2013 | 447 | 0.160 |
Why?
|
| H-2 Antigens | 3 | 2020 | 58 | 0.160 |
Why?
|
| Adult | 11 | 2025 | 29529 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 9 | 1999 | 1028 | 0.160 |
Why?
|
| Growth Inhibitors | 3 | 2004 | 41 | 0.160 |
Why?
|
| Antigens, T-Independent | 1 | 2000 | 4 | 0.160 |
Why?
|
| Green Fluorescent Proteins | 4 | 2014 | 310 | 0.160 |
Why?
|
| Nitriles | 6 | 2005 | 171 | 0.160 |
Why?
|
| Transcription Factors | 4 | 2022 | 1717 | 0.160 |
Why?
|
| Tomography, Optical Coherence | 1 | 2020 | 129 | 0.160 |
Why?
|
| Leadership | 1 | 2022 | 159 | 0.150 |
Why?
|
| Cell Division | 7 | 1999 | 689 | 0.150 |
Why?
|
| North America | 1 | 2020 | 210 | 0.150 |
Why?
|
| Bacterial Proteins | 2 | 2016 | 901 | 0.150 |
Why?
|
| Immunity, Cellular | 6 | 2026 | 187 | 0.150 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 1815 | 0.150 |
Why?
|
| Phosphorylation | 7 | 1999 | 1145 | 0.150 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 588 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 3 | 2013 | 977 | 0.150 |
Why?
|
| Isoenzymes | 3 | 2013 | 272 | 0.150 |
Why?
|
| Cytidine Deaminase | 2 | 2016 | 25 | 0.150 |
Why?
|
| src-Family Kinases | 2 | 1997 | 70 | 0.150 |
Why?
|
| fas Receptor | 2 | 1999 | 73 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 269 | 0.150 |
Why?
|
| Granzymes | 1 | 2019 | 96 | 0.140 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 2888 | 0.140 |
Why?
|
| Crotonates | 4 | 1999 | 12 | 0.140 |
Why?
|
| Thymus Gland | 1 | 2020 | 205 | 0.140 |
Why?
|
| Glucose Tolerance Test | 3 | 2010 | 239 | 0.140 |
Why?
|
| Toluidines | 4 | 1999 | 18 | 0.140 |
Why?
|
| Antigen Presentation | 1 | 2020 | 234 | 0.140 |
Why?
|
| Cell Adhesion | 6 | 1995 | 419 | 0.140 |
Why?
|
| Antibodies, Viral | 2 | 2026 | 338 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 212 | 0.140 |
Why?
|
| Models, Immunological | 2 | 2017 | 86 | 0.140 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 839 | 0.140 |
Why?
|
| Bacterial Vaccines | 2 | 2017 | 44 | 0.130 |
Why?
|
| Drug Resistance | 3 | 1993 | 233 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 682 | 0.130 |
Why?
|
| Mice, SCID | 2 | 2010 | 278 | 0.130 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 249 | 0.130 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 1997 | 11 | 0.130 |
Why?
|
| Mice, Inbred NOD | 6 | 2008 | 227 | 0.130 |
Why?
|
| Neoplasm Proteins | 3 | 1995 | 551 | 0.130 |
Why?
|
| Hybridomas | 3 | 2008 | 61 | 0.130 |
Why?
|
| Oxidoreductases | 1 | 1997 | 112 | 0.130 |
Why?
|
| Clonal Anergy | 1 | 2017 | 32 | 0.130 |
Why?
|
| Mice, Inbred DBA | 3 | 2002 | 146 | 0.130 |
Why?
|
| Adoptive Transfer | 6 | 2016 | 174 | 0.120 |
Why?
|
| Autoantibodies | 3 | 2021 | 286 | 0.120 |
Why?
|
| Central Tolerance | 1 | 2016 | 8 | 0.120 |
Why?
|
| Leukemia, Experimental | 1 | 1996 | 15 | 0.120 |
Why?
|
| Immune Sera | 5 | 2003 | 48 | 0.120 |
Why?
|
| Cell Tracking | 1 | 2016 | 14 | 0.120 |
Why?
|
| Neutralization Tests | 2 | 2014 | 74 | 0.120 |
Why?
|
| Kinetics | 5 | 2016 | 1476 | 0.120 |
Why?
|
| Vaccines | 2 | 2014 | 86 | 0.120 |
Why?
|
| Integrases | 1 | 2016 | 68 | 0.120 |
Why?
|
| Transplant Recipients | 1 | 2018 | 182 | 0.120 |
Why?
|
| Cell Movement | 1 | 2020 | 814 | 0.120 |
Why?
|
| RNA, Untranslated | 1 | 2016 | 70 | 0.120 |
Why?
|
| Polysaccharides | 2 | 2014 | 99 | 0.120 |
Why?
|
| Luminescent Proteins | 1 | 2016 | 142 | 0.120 |
Why?
|
| Biocompatible Materials | 2 | 2014 | 204 | 0.120 |
Why?
|
| Lymphotoxin-alpha | 2 | 1993 | 41 | 0.120 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2015 | 12 | 0.120 |
Why?
|
| 5'-Nucleotidase | 1 | 2015 | 16 | 0.120 |
Why?
|
| Peptide Fragments | 3 | 2012 | 480 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 342 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 338 | 0.110 |
Why?
|
| Drug Synergism | 3 | 2013 | 317 | 0.110 |
Why?
|
| Hemolysin Proteins | 2 | 2022 | 32 | 0.110 |
Why?
|
| Lymphocytes | 3 | 2008 | 461 | 0.110 |
Why?
|
| Sirolimus | 2 | 2013 | 182 | 0.110 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 143 | 0.110 |
Why?
|
| Plasmodium | 1 | 2014 | 11 | 0.110 |
Why?
|
| Organizational Objectives | 1 | 2015 | 23 | 0.110 |
Why?
|
| Pyrimidine Nucleotides | 3 | 1999 | 7 | 0.110 |
Why?
|
| Malaria, Falciparum | 1 | 2014 | 17 | 0.110 |
Why?
|
| Bacterial Toxins | 2 | 2022 | 113 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 337 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 3 | 2016 | 881 | 0.110 |
Why?
|
| Gene Expression | 3 | 2013 | 1320 | 0.110 |
Why?
|
| Transfection | 4 | 1998 | 883 | 0.110 |
Why?
|
| Prognosis | 2 | 2014 | 4116 | 0.100 |
Why?
|
| Rabbits | 2 | 2013 | 581 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2015 | 212 | 0.100 |
Why?
|
| Macromolecular Substances | 1 | 2014 | 162 | 0.100 |
Why?
|
| Antigen-Antibody Complex | 1 | 2014 | 89 | 0.100 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2014 | 25 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 1996 | 419 | 0.100 |
Why?
|
| Research Report | 1 | 2014 | 43 | 0.100 |
Why?
|
| CD2 Antigens | 4 | 1994 | 22 | 0.100 |
Why?
|
| Antigens, CD20 | 2 | 2012 | 34 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 199 | 0.100 |
Why?
|
| Nanostructures | 1 | 2014 | 93 | 0.100 |
Why?
|
| Intestine, Small | 4 | 1998 | 318 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 1999 | 1950 | 0.100 |
Why?
|
| Protein Kinase C | 2 | 2013 | 267 | 0.100 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 64 | 0.100 |
Why?
|
| Dermatitis | 1 | 2013 | 34 | 0.100 |
Why?
|
| Drug Therapy, Combination | 6 | 1998 | 764 | 0.100 |
Why?
|
| Vaccines, Synthetic | 1 | 2013 | 59 | 0.090 |
Why?
|
| Immunoglobulins | 1 | 2013 | 123 | 0.090 |
Why?
|
| Injections, Intravenous | 2 | 2003 | 212 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1782 | 0.090 |
Why?
|
| Complement C4b | 1 | 2012 | 33 | 0.090 |
Why?
|
| Syndecan-1 | 1 | 2012 | 18 | 0.090 |
Why?
|
| Malaria | 1 | 2012 | 28 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1109 | 0.090 |
Why?
|
| Middle Aged | 9 | 2025 | 29419 | 0.090 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 3 | 1997 | 34 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 1565 | 0.090 |
Why?
|
| Binding, Competitive | 3 | 1999 | 136 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2022 | 373 | 0.090 |
Why?
|
| Escherichia coli | 1 | 2014 | 572 | 0.090 |
Why?
|
| Heat-Shock Proteins | 2 | 2014 | 178 | 0.090 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 2018 | 122 | 0.090 |
Why?
|
| Genotype | 1 | 2016 | 1888 | 0.090 |
Why?
|
| Group Processes | 2 | 2023 | 30 | 0.090 |
Why?
|
| Viral Proteins | 2 | 2006 | 252 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 116 | 0.090 |
Why?
|
| Species Specificity | 4 | 2000 | 690 | 0.080 |
Why?
|
| Antigens, Neoplasm | 2 | 2005 | 361 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 299 | 0.080 |
Why?
|
| Methylprednisolone | 1 | 2011 | 65 | 0.080 |
Why?
|
| Leukocyte Transfusion | 1 | 2010 | 15 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 1995 | 77 | 0.080 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 1990 | 12 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2022 | 4823 | 0.080 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2014 | 278 | 0.080 |
Why?
|
| Injections, Intraperitoneal | 2 | 2003 | 102 | 0.080 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2010 | 37 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2006 | 1751 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1992 | 168 | 0.080 |
Why?
|
| Crosses, Genetic | 1 | 2010 | 165 | 0.080 |
Why?
|
| Th17 Cells | 1 | 2011 | 97 | 0.080 |
Why?
|
| Pancreatic Diseases | 1 | 2010 | 61 | 0.080 |
Why?
|
| Cell Death | 3 | 2007 | 257 | 0.080 |
Why?
|
| Cell Separation | 3 | 2024 | 200 | 0.080 |
Why?
|
| CD28 Antigens | 2 | 2004 | 94 | 0.080 |
Why?
|
| CD58 Antigens | 3 | 1994 | 5 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 922 | 0.080 |
Why?
|
| Interferon-beta | 1 | 2010 | 127 | 0.070 |
Why?
|
| Drug Resistance, Microbial | 2 | 1999 | 63 | 0.070 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2011 | 206 | 0.070 |
Why?
|
| Monocytes | 1 | 1990 | 219 | 0.070 |
Why?
|
| Ischemia | 2 | 2014 | 262 | 0.070 |
Why?
|
| Gene Knock-In Techniques | 1 | 2009 | 31 | 0.070 |
Why?
|
| Aging | 1 | 2014 | 770 | 0.070 |
Why?
|
| Obesity | 1 | 2016 | 1061 | 0.070 |
Why?
|
| Heart | 2 | 2016 | 527 | 0.070 |
Why?
|
| Microspheres | 1 | 1988 | 91 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 8 | 1999 | 1255 | 0.070 |
Why?
|
| Lipopolysaccharides | 5 | 2017 | 313 | 0.070 |
Why?
|
| Biopsy | 1 | 2012 | 1224 | 0.070 |
Why?
|
| Tandem Repeat Sequences | 1 | 2008 | 31 | 0.070 |
Why?
|
| Bystander Effect | 1 | 2008 | 14 | 0.070 |
Why?
|
| Interleukin-18 | 1 | 2008 | 27 | 0.070 |
Why?
|
| Luminescence | 1 | 2008 | 20 | 0.070 |
Why?
|
| Interleukin-1 | 1 | 2008 | 72 | 0.070 |
Why?
|
| DNA, Viral | 2 | 1999 | 238 | 0.070 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2008 | 78 | 0.070 |
Why?
|
| Fibroblasts | 3 | 2003 | 767 | 0.070 |
Why?
|
| Quinaldines | 2 | 1998 | 7 | 0.070 |
Why?
|
| Reference Values | 2 | 2006 | 608 | 0.070 |
Why?
|
| Ovalbumin | 2 | 2022 | 105 | 0.070 |
Why?
|
| Protein Structure, Secondary | 3 | 2014 | 340 | 0.070 |
Why?
|
| Receptors, Interleukin-2 | 3 | 2005 | 68 | 0.070 |
Why?
|
| Cross Infection | 1 | 2009 | 155 | 0.070 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2008 | 62 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2013 | 830 | 0.070 |
Why?
|
| Complement System Proteins | 1 | 2008 | 87 | 0.070 |
Why?
|
| In Vitro Techniques | 3 | 1995 | 945 | 0.060 |
Why?
|
| Blotting, Northern | 2 | 1999 | 239 | 0.060 |
Why?
|
| Ligands | 1 | 2008 | 486 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 2 | 2013 | 68 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2014 | 2585 | 0.060 |
Why?
|
| Interferon Type I | 1 | 2008 | 170 | 0.060 |
Why?
|
| Protein Binding | 3 | 2020 | 1554 | 0.060 |
Why?
|
| Leukemia, Erythroblastic, Acute | 3 | 1992 | 28 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2001 | 780 | 0.060 |
Why?
|
| Receptors, Antigen | 1 | 1986 | 13 | 0.060 |
Why?
|
| Rats, Inbred ACI | 4 | 2001 | 24 | 0.060 |
Why?
|
| Rats, Inbred BN | 5 | 2005 | 37 | 0.060 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 1 | 2026 | 9 | 0.060 |
Why?
|
| Amino Acid Sequence | 4 | 2013 | 2005 | 0.060 |
Why?
|
| Type C Phospholipases | 2 | 1996 | 26 | 0.060 |
Why?
|
| Salivary Glands | 1 | 2006 | 20 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 2783 | 0.060 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2026 | 85 | 0.060 |
Why?
|
| Embolism | 1 | 2006 | 32 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2006 | 161 | 0.060 |
Why?
|
| Caspases | 1 | 2006 | 151 | 0.060 |
Why?
|
| Lectins, C-Type | 1 | 2006 | 74 | 0.060 |
Why?
|
| Age Factors | 3 | 2014 | 1962 | 0.060 |
Why?
|
| Carrageenan | 1 | 1985 | 9 | 0.060 |
Why?
|
| Portal Vein | 1 | 2006 | 121 | 0.060 |
Why?
|
| Bone Marrow | 2 | 1998 | 418 | 0.060 |
Why?
|
| Enzyme Inhibitors | 3 | 1999 | 642 | 0.060 |
Why?
|
| Organ Preservation | 2 | 2014 | 139 | 0.060 |
Why?
|
| Neoplasms | 3 | 2025 | 3334 | 0.050 |
Why?
|
| Fasting | 2 | 1995 | 166 | 0.050 |
Why?
|
| Molecular Sequence Data | 5 | 2012 | 2896 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2026 | 174 | 0.050 |
Why?
|
| Autoantigens | 2 | 2016 | 145 | 0.050 |
Why?
|
| Hyperglycemia | 1 | 2006 | 186 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2025 | 78 | 0.050 |
Why?
|
| Tilapia | 1 | 2004 | 1 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2004 | 811 | 0.050 |
Why?
|
| Interleukin-4 | 2 | 2002 | 136 | 0.050 |
Why?
|
| Infant | 2 | 2022 | 3327 | 0.050 |
Why?
|
| Bias | 1 | 2024 | 139 | 0.050 |
Why?
|
| Immunity | 2 | 2022 | 160 | 0.050 |
Why?
|
| Sporozoites | 2 | 2014 | 3 | 0.050 |
Why?
|
| Antibodies, Protozoan | 2 | 2014 | 47 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2004 | 188 | 0.050 |
Why?
|
| Metabolomics | 1 | 2024 | 106 | 0.050 |
Why?
|
| Stem Cells | 1 | 2006 | 395 | 0.050 |
Why?
|
| Young Adult | 4 | 2022 | 7504 | 0.050 |
Why?
|
| Chimerism | 1 | 2023 | 38 | 0.050 |
Why?
|
| Binding Sites, Antibody | 1 | 2003 | 47 | 0.050 |
Why?
|
| Cloning, Organism | 1 | 2003 | 19 | 0.050 |
Why?
|
| Antibody Affinity | 1 | 2003 | 38 | 0.050 |
Why?
|
| Myocardium | 2 | 2004 | 578 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 312 | 0.050 |
Why?
|
| Influenza, Human | 1 | 2026 | 357 | 0.050 |
Why?
|
| Germany | 1 | 2022 | 84 | 0.050 |
Why?
|
| Body Weight | 3 | 2016 | 455 | 0.050 |
Why?
|
| Virus Replication | 2 | 2005 | 291 | 0.050 |
Why?
|
| beta-N-Acetylglucosaminylglycopeptide beta-1,4-Galactosyltransferase | 1 | 2002 | 2 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2006 | 2063 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2001 | 679 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2001 | 9 | 0.040 |
Why?
|
| Hemin | 1 | 2001 | 6 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 58 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 1133 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2003 | 242 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 1 | 2001 | 62 | 0.040 |
Why?
|
| Fas Ligand Protein | 2 | 1998 | 47 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2021 | 38 | 0.040 |
Why?
|
| Palatine Tonsil | 1 | 2021 | 34 | 0.040 |
Why?
|
| Drug Combinations | 2 | 1998 | 201 | 0.040 |
Why?
|
| Scrapie | 1 | 2001 | 2 | 0.040 |
Why?
|
| Clostridium botulinum | 1 | 2000 | 2 | 0.040 |
Why?
|
| PrPSc Proteins | 1 | 2001 | 21 | 0.040 |
Why?
|
| Astrocytes | 1 | 2001 | 142 | 0.040 |
Why?
|
| Janus Kinase 3 | 2 | 1998 | 9 | 0.040 |
Why?
|
| Biolistics | 2 | 1998 | 4 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2000 | 30 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 218 | 0.040 |
Why?
|
| Neuromuscular Diseases | 1 | 2000 | 26 | 0.040 |
Why?
|
| Financing, Organized | 1 | 2020 | 14 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 63 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 4025 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 79 | 0.040 |
Why?
|
| Adolescent | 4 | 2022 | 10077 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 2020 | 6 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2001 | 226 | 0.040 |
Why?
|
| Trisaccharides | 1 | 2000 | 13 | 0.040 |
Why?
|
| Bortezomib | 1 | 2020 | 83 | 0.040 |
Why?
|
| Mice, Congenic | 1 | 2019 | 12 | 0.040 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 1999 | 18 | 0.040 |
Why?
|
| Research Personnel | 1 | 2020 | 87 | 0.040 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1999 | 10 | 0.040 |
Why?
|
| Foscarnet | 1 | 1999 | 9 | 0.040 |
Why?
|
| Lymphocyte Transfusion | 1 | 2019 | 39 | 0.040 |
Why?
|
| Umbilical Veins | 1 | 1999 | 45 | 0.040 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1999 | 22 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 1999 | 94 | 0.040 |
Why?
|
| Receptors, Growth Factor | 1 | 1999 | 52 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1999 | 85 | 0.040 |
Why?
|
| B7-1 Antigen | 2 | 2013 | 75 | 0.040 |
Why?
|
| Staphylococcus epidermidis | 1 | 2019 | 16 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1999 | 86 | 0.040 |
Why?
|
| Neuropeptides | 1 | 1999 | 113 | 0.040 |
Why?
|
| Pancreas | 1 | 2001 | 269 | 0.040 |
Why?
|
| Models, Biological | 2 | 1998 | 1807 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1999 | 20 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 1999 | 399 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 219 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 2001 | 210 | 0.040 |
Why?
|
| Caspase 1 | 1 | 1998 | 22 | 0.040 |
Why?
|
| Leukemia, T-Cell | 1 | 1998 | 17 | 0.030 |
Why?
|
| HT29 Cells | 1 | 1998 | 50 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 183 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 1998 | 65 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1998 | 65 | 0.030 |
Why?
|
| Binding Sites | 2 | 2017 | 1159 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 750 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 1998 | 60 | 0.030 |
Why?
|
| Stimulation, Chemical | 2 | 1996 | 54 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 1998 | 116 | 0.030 |
Why?
|
| Cell Survival | 2 | 2001 | 1014 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 1998 | 89 | 0.030 |
Why?
|
| Transcriptome | 1 | 2024 | 820 | 0.030 |
Why?
|
| Cytidine Triphosphate | 1 | 1997 | 3 | 0.030 |
Why?
|
| Uridine Triphosphate | 1 | 1997 | 7 | 0.030 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 1997 | 37 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 1998 | 89 | 0.030 |
Why?
|
| Complement C3 | 1 | 1997 | 62 | 0.030 |
Why?
|
| Immunotherapy, Active | 1 | 2017 | 15 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2021 | 357 | 0.030 |
Why?
|
| Vaccination | 1 | 2020 | 323 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 1997 | 15 | 0.030 |
Why?
|
| Nucleotide Motifs | 1 | 2017 | 50 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 267 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.030 |
Why?
|
| Particle Size | 1 | 2017 | 129 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 473 | 0.030 |
Why?
|
| Cell Membrane | 4 | 2000 | 673 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 1997 | 217 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1031 | 0.030 |
Why?
|
| Glioma | 1 | 1999 | 309 | 0.030 |
Why?
|
| Child | 2 | 2022 | 7680 | 0.030 |
Why?
|
| Rifabutin | 1 | 1996 | 3 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 1996 | 11 | 0.030 |
Why?
|
| Quinones | 1 | 1996 | 9 | 0.030 |
Why?
|
| Lactams, Macrocyclic | 1 | 1996 | 15 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 1996 | 31 | 0.030 |
Why?
|
| Research Design | 1 | 2021 | 660 | 0.030 |
Why?
|
| Benzoquinones | 1 | 1996 | 27 | 0.030 |
Why?
|
| Clindamycin | 1 | 2016 | 14 | 0.030 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2016 | 19 | 0.030 |
Why?
|
| Thymocytes | 1 | 2016 | 33 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 1999 | 516 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1567 | 0.030 |
Why?
|
| Leukemia | 2 | 2008 | 308 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2022 | 10960 | 0.030 |
Why?
|
| Antigens, Ly | 1 | 1996 | 37 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2017 | 120 | 0.030 |
Why?
|
| Survival Rate | 1 | 2021 | 2041 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2014 | 557 | 0.030 |
Why?
|
| Aged | 4 | 2020 | 21750 | 0.030 |
Why?
|
| Verapamil | 2 | 1993 | 32 | 0.030 |
Why?
|
| Diet, Fat-Restricted | 1 | 2016 | 30 | 0.030 |
Why?
|
| PrPC Proteins | 1 | 1996 | 13 | 0.030 |
Why?
|
| Rhodamine 123 | 2 | 1993 | 8 | 0.030 |
Why?
|
| Rhodamines | 2 | 1993 | 20 | 0.030 |
Why?
|
| Neurotoxins | 1 | 1996 | 45 | 0.030 |
Why?
|
| Genistein | 1 | 1995 | 16 | 0.030 |
Why?
|
| Isoflavones | 1 | 1995 | 13 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1995 | 0.030 |
Why?
|
| Prions | 1 | 1996 | 53 | 0.030 |
Why?
|
| Sulfhydryl Reagents | 1 | 1995 | 9 | 0.030 |
Why?
|
| Kupffer Cells | 1 | 1995 | 14 | 0.030 |
Why?
|
| Vanadates | 1 | 1995 | 32 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1996 | 158 | 0.030 |
Why?
|
| Phospholipase C gamma | 1 | 1995 | 15 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 1995 | 22 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1129 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 212 | 0.030 |
Why?
|
| Anopheles | 1 | 2014 | 4 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1535 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2015 | 135 | 0.030 |
Why?
|
| Recurrence | 3 | 2008 | 1254 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 2013 | 0.030 |
Why?
|
| Macrophage-1 Antigen | 1 | 1994 | 18 | 0.030 |
Why?
|
| Plasmodium falciparum | 1 | 2014 | 57 | 0.030 |
Why?
|
| Germ-Free Life | 1 | 2014 | 88 | 0.030 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2014 | 22 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 916 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2014 | 20 | 0.030 |
Why?
|
| Empyema | 1 | 1994 | 9 | 0.030 |
Why?
|
| Single-Chain Antibodies | 1 | 2014 | 21 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 1996 | 250 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 4000 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 137 | 0.030 |
Why?
|
| Alum Compounds | 1 | 2013 | 5 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2014 | 95 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2014 | 74 | 0.020 |
Why?
|
| Protein Kinase C-theta | 1 | 2013 | 16 | 0.020 |
Why?
|
| Abdomen | 1 | 1994 | 120 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2013 | 42 | 0.020 |
Why?
|
| Fungal Proteins | 1 | 2014 | 148 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1993 | 73 | 0.020 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2013 | 16 | 0.020 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2013 | 17 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2013 | 43 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 79 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 1994 | 198 | 0.020 |
Why?
|
| Polyenes | 1 | 1993 | 8 | 0.020 |
Why?
|
| Nitrophenols | 1 | 2013 | 11 | 0.020 |
Why?
|
| Tritium | 1 | 1993 | 113 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 700 | 0.020 |
Why?
|
| Propylamines | 1 | 1993 | 7 | 0.020 |
Why?
|
| Thymidine | 1 | 1993 | 58 | 0.020 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2013 | 51 | 0.020 |
Why?
|
| Organophosphonates | 1 | 2013 | 46 | 0.020 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1992 | 11 | 0.020 |
Why?
|
| Rituximab | 1 | 2013 | 135 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2013 | 95 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1999 | 1105 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 198 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1993 | 239 | 0.020 |
Why?
|
| Autophagy | 1 | 2014 | 177 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1996 | 993 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 1991 | 71 | 0.020 |
Why?
|
| Receptors, Concanavalin A | 1 | 1991 | 1 | 0.020 |
Why?
|
| Phagocytosis | 2 | 1995 | 117 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2012 | 207 | 0.020 |
Why?
|
| Gamma Rays | 1 | 1991 | 72 | 0.020 |
Why?
|
| Alpha-Globulins | 1 | 1990 | 11 | 0.020 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1990 | 16 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1990 | 49 | 0.020 |
Why?
|
| Lymphoma | 2 | 1990 | 254 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2019 | 2679 | 0.020 |
Why?
|
| Calcium | 1 | 1995 | 1196 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 1990 | 39 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1990 | 41 | 0.020 |
Why?
|
| Skin Diseases | 1 | 1992 | 176 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 1995 | 425 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 731 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 1991 | 179 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1990 | 38 | 0.020 |
Why?
|
| Killer Factors, Yeast | 1 | 1989 | 1 | 0.020 |
Why?
|
| Cell-Free System | 1 | 1989 | 45 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 1989 | 20 | 0.020 |
Why?
|
| Periodic Acid | 1 | 1988 | 4 | 0.020 |
Why?
|
| Tissue and Organ Procurement | 1 | 2014 | 423 | 0.020 |
Why?
|
| Neuraminidase | 1 | 1988 | 46 | 0.020 |
Why?
|
| Trypsin | 1 | 1988 | 92 | 0.020 |
Why?
|
| Oligosaccharides | 1 | 1988 | 28 | 0.020 |
Why?
|
| Biological Assay | 1 | 1989 | 82 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2009 | 93 | 0.020 |
Why?
|
| Clone Cells | 1 | 1989 | 220 | 0.020 |
Why?
|
| Pluripotent Stem Cells | 1 | 2008 | 38 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 794 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 889 | 0.020 |
Why?
|
| Base Sequence | 2 | 2001 | 2222 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 1998 | 161 | 0.020 |
Why?
|
| Rodentia | 1 | 2007 | 49 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 1995 | 1285 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 332 | 0.020 |
Why?
|
| Rosette Formation | 1 | 1986 | 28 | 0.020 |
Why?
|
| Thioglycolates | 1 | 1986 | 2 | 0.020 |
Why?
|
| Mycobacterium bovis | 1 | 1986 | 16 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 2 | 1997 | 38 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2008 | 330 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 1610 | 0.010 |
Why?
|
| Rose Bengal | 1 | 1985 | 3 | 0.010 |
Why?
|
| Colorimetry | 1 | 1985 | 8 | 0.010 |
Why?
|
| Polyelectrolytes | 1 | 1985 | 7 | 0.010 |
Why?
|
| Endocytosis | 1 | 1986 | 187 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1985 | 161 | 0.010 |
Why?
|
| Carbohydrates | 1 | 1985 | 40 | 0.010 |
Why?
|
| Alkynes | 1 | 2005 | 20 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2004 | 37 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1991 | 1445 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 566 | 0.010 |
Why?
|
| Neutrophils | 1 | 1986 | 346 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2008 | 709 | 0.010 |
Why?
|
| Membranes | 1 | 2004 | 35 | 0.010 |
Why?
|
| Polymers | 1 | 1985 | 225 | 0.010 |
Why?
|
| Proteins | 1 | 1989 | 804 | 0.010 |
Why?
|
| Temperature | 1 | 1985 | 442 | 0.010 |
Why?
|
| Nuclear Transfer Techniques | 1 | 2003 | 15 | 0.010 |
Why?
|
| Immunoglobulin D | 1 | 2002 | 6 | 0.010 |
Why?
|
| Leukosialin | 1 | 2002 | 16 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 220 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 356 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 31 | 0.010 |
Why?
|
| Pregnatrienes | 1 | 2001 | 14 | 0.010 |
Why?
|
| Phenanthrolines | 1 | 2001 | 8 | 0.010 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2001 | 25 | 0.010 |
Why?
|
| Butadienes | 1 | 2001 | 33 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2001 | 52 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2001 | 115 | 0.010 |
Why?
|
| Calcineurin Inhibitors | 1 | 2002 | 55 | 0.010 |
Why?
|
| Free Radicals | 1 | 2001 | 72 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2001 | 71 | 0.010 |
Why?
|
| Prednisone | 1 | 2002 | 251 | 0.010 |
Why?
|
| Flavonoids | 1 | 2001 | 86 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2001 | 147 | 0.010 |
Why?
|
| Endopeptidase K | 1 | 2001 | 12 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 269 | 0.010 |
Why?
|
| Creatinine | 1 | 2002 | 313 | 0.010 |
Why?
|
| Vero Cells | 1 | 2001 | 98 | 0.010 |
Why?
|
| Anemia | 1 | 2002 | 135 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 290 | 0.010 |
Why?
|
| Antioxidants | 1 | 2001 | 236 | 0.010 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2000 | 12 | 0.010 |
Why?
|
| GA-Binding Protein Transcription Factor | 1 | 1999 | 2 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 630 | 0.010 |
Why?
|
| Splanchnic Circulation | 1 | 1999 | 14 | 0.010 |
Why?
|
| Neurons | 2 | 2001 | 1619 | 0.010 |
Why?
|
| Liver Circulation | 1 | 1999 | 28 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 1999 | 85 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 1999 | 92 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 2080 | 0.010 |
Why?
|
| Thalamus | 1 | 2001 | 136 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 124 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 7386 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2001 | 525 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1999 | 228 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2001 | 489 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1998 | 163 | 0.010 |
Why?
|
| STAT6 Transcription Factor | 1 | 1998 | 32 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2001 | 571 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1997 | 30 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1997 | 65 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1999 | 298 | 0.010 |
Why?
|
| Hematoxylin | 1 | 1997 | 9 | 0.010 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 1997 | 14 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1999 | 615 | 0.010 |
Why?
|
| Hippocampus | 1 | 2001 | 462 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 1998 | 286 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 1945 | 0.010 |
Why?
|
| Circular Dichroism | 1 | 1996 | 118 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1996 | 71 | 0.010 |
Why?
|
| PC12 Cells | 1 | 1996 | 112 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1995 | 10 | 0.010 |
Why?
|
| Marine Toxins | 1 | 1995 | 4 | 0.010 |
Why?
|
| Okadaic Acid | 1 | 1995 | 10 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 1995 | 25 | 0.010 |
Why?
|
| Ethers, Cyclic | 1 | 1995 | 8 | 0.010 |
Why?
|
| Oxazoles | 1 | 1995 | 14 | 0.010 |
Why?
|
| Cations, Divalent | 1 | 1995 | 34 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1995 | 58 | 0.010 |
Why?
|
| Naphthalenes | 1 | 1995 | 43 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 1997 | 388 | 0.010 |
Why?
|
| Bile | 1 | 1995 | 60 | 0.010 |
Why?
|
| Glycogen | 1 | 1995 | 58 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1996 | 523 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1995 | 299 | 0.010 |
Why?
|
| Duodenal Neoplasms | 1 | 1994 | 21 | 0.010 |
Why?
|
| Ileostomy | 1 | 1994 | 28 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 1995 | 200 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1995 | 419 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1996 | 518 | 0.010 |
Why?
|
| Leiomyosarcoma | 1 | 1994 | 48 | 0.010 |
Why?
|
| Weight Gain | 1 | 1994 | 134 | 0.010 |
Why?
|
| Chloroquine | 1 | 1993 | 15 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 1993 | 54 | 0.010 |
Why?
|
| Stearic Acids | 1 | 1993 | 12 | 0.010 |
Why?
|
| Perforin | 1 | 1993 | 56 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1994 | 578 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1995 | 412 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1995 | 923 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1992 | 18 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1994 | 582 | 0.010 |
Why?
|
| Actins | 1 | 1995 | 480 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1996 | 409 | 0.010 |
Why?
|
| Probability | 1 | 1993 | 356 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1992 | 215 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1991 | 19 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 889 | 0.010 |
Why?
|
| Biological Transport | 1 | 1991 | 401 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 895 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1993 | 382 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1990 | 43 | 0.000 |
Why?
|
| RNA | 1 | 1993 | 595 | 0.000 |
Why?
|
| Interferons | 1 | 1989 | 114 | 0.000 |
Why?
|
| DNA | 1 | 1993 | 1274 | 0.000 |
Why?
|